Semaglutide Reduces Heavy Drinking in Alcohol Use Disorder with Obesity | The Lancet

Introduction

Alcohol use disorder (AUD) remains a major global health challenge with limited pharmacologic treatment options and persistently high relapse rates. Although behavioural therapies remain foundational, currently approved medications offer modest efficacy, creating a substantial need for more effective therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in obesity and diabetes, have emerged as promising candidates owing to their effects on reward signalling, appetite regulation and addictive behaviours.

Problem Statement

Effective pharmacotherapy for AUD remains limited, particularly in patients with coexisting obesity, a phenotype increasingly recognized to share overlapping neurobiological and metabolic pathways with addictive behaviour. While preclinical and early human data have suggested that GLP-1RAs may reduce alcohol consumption, robust randomized evidence in treatment-seeking patients with clinically significant AUD has been lacking.

Summary

This randomized, placebo-controlled trial demonstrates that once-weekly semaglutide significantly reduces heavy drinking in treatment-seeking patients with moderate-to-severe AUD and comorbid obesity. Over 26 weeks, semaglutide produced greater reductions in heavy drinking days, total alcohol intake, alcohol craving and WHO drinking risk levels compared with placebo, while also improving several objective alcohol-related biomarkers. These benefits were accompanied by substantial reductions in body weight, waist circumference and glycated hemoglobin, supporting a broader metabolic benefit in this high-risk population. The treatment was generally well tolerated, with predominantly mild-to-moderate gastrointestinal adverse effects consistent with the known safety profile of semaglutide. Importantly, this is the first randomized trial to show clinically meaningful reductions in alcohol consumption with semaglutide in treatment-seeking individuals, supporting GLP-1 receptor agonism as a promising therapeutic strategy for AUD. Although larger and more diverse studies are needed before routine clinical adoption, these findings position semaglutide as a potentially important dual-purpose intervention for patients with coexisting alcohol use disorder and obesity.